Researchers found that patients with type 2 diabetes who used neutral protamine Hagedorn insulin as a third-line therapy were more likely to discontinue its use and had an increased risk for hypoglycemia than those on DPP-4 inhibitors. The findings in the Journal of Diabetes Research, based on 54,318 patients, showed the groups had a similar risk for cardiovascular events.
Study compares efficacy of NPH insulin, DPP-4 inhibitors in type 2 diabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.